^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    ACVR1 inhibitor

    Related drugs:
    14d
    Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms (clinicaltrials.gov)
    P2, N=27, Recruiting, University of Washington | Not yet recruiting --> Recruiting
    Enrollment open
    |
    azacitidine • Inqovi (decitabine/cedazuridine) • Vonjo (pacritinib)
    15d
    Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, United Lincolnshire Hospitals NHS Trust
    New P2 trial
    |
    Ojjaara (momelotinib) • bomedemstat (MK-3543)
    17d
    GFM-VEXAS-MMB: Momelotinib in VEXAS syndrome (2024-519779-24-00)
    P1/2, N=57, Recruiting, Groupe Francophone Des Myelodysplasies
    New P1/2 trial
    |
    Ojjaara (momelotinib)
    23d
    Momelotinib During and After HCT in Myelofibrosis (clinicaltrials.gov)
    P1, N=28, Recruiting, Massachusetts General Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • ASXL1 (ASXL Transcriptional Regulator 1) • SRSF2 (Serine and arginine rich splicing factor 2) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    Ojjaara (momelotinib)
    24d
    M-HArbOr: Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial primary completion date: Dec 2027 --> Mar 2028
    Trial primary completion date
    |
    azacitidine • Ojjaara (momelotinib)
    1m
    MDS: Pacritinib With Aza for Upfront Myelodysplastic Syndrome (clinicaltrials.gov)
    P1/2, N=25, Not yet recruiting, Thomas Jefferson University
    New P1/2 trial
    |
    azacitidine • Vonjo (pacritinib)
    2ms
    Pharmacologic Inhibition of JAK1/2 Potentiates Aminoglycoside-Induced Ototoxicity. (PubMed, Otol Neurotol)
    JAK1 and JAK2 inhibition worsens cochlear damage in mice exposed to aminoglycosides.
    Journal
    |
    JAK1 (Janus Kinase 1) • CDH2 (Cadherin 2) • CDH3 (Cadherin 3) • CDH23 (Cadherin Related 23)
    |
    Ojjaara (momelotinib)
    2ms
    A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS) (clinicaltrials.gov)
    P2, N=78, Active, not recruiting, Swedish Orphan Biovitrum | Trial completion date: Aug 2027 --> May 2028 | Trial primary completion date: Aug 2027 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Vonjo (pacritinib)
    3ms
    IKBKE modulates autophagy and progestin resistance in endometrial cancer. (PubMed, Front Oncol)
    A progestin-resistant EC cell line was established to assess the effects of IKBKE knockdown and treatment with CYT387, a selective IKBKE inhibitor...These findings highlight the crucial role of IKBKE in regulating autophagy and mediating progestin resistance in EC. This study provides new insights into IKBKE as a potential molecular target that contributes to understanding the mechanisms underlying progestin resistance in endometrial cancer.
    Journal
    |
    IKBKE (Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Epsilon)
    |
    Ojjaara (momelotinib)
    3ms
    A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS) (clinicaltrials.gov)
    P2, N=78, Active, not recruiting, Swedish Orphan Biovitrum | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Vonjo (pacritinib)
    3ms
    Momelotinib in VEXAS Syndrome (clinicaltrials.gov)
    P2, N=57, Recruiting, Groupe Francophone des Myelodysplasies | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Ojjaara (momelotinib)
    3ms
    To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva (clinicaltrials.gov)
    P2, N=98, Recruiting, Incyte Corporation | Trial primary completion date: Feb 2025 --> Jul 2027
    Trial primary completion date
    |
    zilurgisertib (INCB00928)